Patents Examined by Golam M. Shameem
  • Patent number: 11685739
    Abstract: One aspect of the invention provides a composition of novel high penetration compositions (HPC) or a high penetration prodrug (HPP) for treatment of Parkinson's disease. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
    Type: Grant
    Filed: August 9, 2021
    Date of Patent: June 27, 2023
    Assignee: TECHFIELDS PHARMA CO., LTD.
    Inventors: Chongxi Yu, Lina Xu
  • Patent number: 11684629
    Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: June 27, 2023
    Assignee: MELINTA SUBSIDIARY CORP.
    Inventors: Gavin Hirst, Raja Reddy, Scott J. Hecker, Maxim Totrov, David C. Griffith, Olga Lomovskaya, Michael N. Dudley, Serge Henri Boyer
  • Patent number: 11680075
    Abstract: The present invention relates to an application of 4-MePhNHLi, in particular, to an application of 4-MePhNHLi in catalyzing hydroboration reaction of imine and borane. A catalyst, borane, and imine are stirred and mixed uniformly in sequence for reaction for 1-2 hours, the reaction is terminated by exposure to air, and the solvent in the reaction liquid is removed under reduced pressure to obtain borate esters having different substituents. According to the present invention, 4-MePhNHLi can catalyze hydroboration reaction of imine and borane at high activity at room temperature, the amount of catalyst is only 4-5 mol % of the molar mass of imine, and the reaction can reach a yield of more than 90%; compared with an existing catalytic system, simple 4-MePhNHLi is used, the reaction conditions are mild, and the yield of borate esters having different substituents can reach 99% in optimized conditions.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: June 20, 2023
    Assignee: SOOCHOW UNIVERSITY
    Inventors: Mingqiang Xue, Xiaojuan Xu, Dandan Yan
  • Patent number: 11680034
    Abstract: Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging, or for modulating one or more energy biomarkers, normalizing one or more energy biomarkers, or enhancing one or more energy biomarkers, wherein the compounds are tocopherol quinone derivatives. Further disclosed are compounds, compositions, and methods for treatment of, or prophylaxis against, radiation exposure.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: June 20, 2023
    Assignee: PTC Therapeutics, Inc.
    Inventors: Andrew W. Hinman, Steven J. Richards
  • Patent number: 11673874
    Abstract: The present invention relates to a process for the production of chromanol derivatives, more specifically to a process for preparing a compound of the general formula I wherein R1, R2 and R3 independently of each other are selected from hydrogen and methyl, R4 is selected from C-1-C6-alkyl, and X is selected from C1-C20-alkyl and C2-C20-alkenyl.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: June 13, 2023
    Assignee: BASF SE
    Inventors: Melanie Weingarten, Wolfgang Siegel, Michael Puhl
  • Patent number: 11673852
    Abstract: Metabolism-resistant fenfluramine analogs are provided. The subject fenfluramine analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of suppressing appetite in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided.
    Type: Grant
    Filed: April 5, 2022
    Date of Patent: June 13, 2023
    Assignee: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. Farr, Brooks M. Boyd
  • Patent number: 11673885
    Abstract: The present disclosure provides ?-diketones or analogs thereof, that activate Wnt/?-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: June 13, 2023
    Assignee: BioSplice Therapeutics, Inc.
    Inventors: Sunil Kumar KC, David Mark Wallace, John Hood, Charlene F. Barroga
  • Patent number: 11667636
    Abstract: Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein A, B, C, D, E, G, W, Y, Z, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: June 6, 2023
    Assignee: ESCIENT PHARMACEUTICALS, INC.
    Inventors: Marion Lanier, Marcos Sainz, Marcus Boehm, Liming Huang, Esther Martinborough, Brandon Selfridge, Adam Yeager
  • Patent number: 11654424
    Abstract: The present disclosure is directed to method embodiments for making anhydrous lanthanide halide complexes. At least some embodiments comprise making a lanthanide halide complex by reacting a lanthanide metal oxide with an oxygen scavenger and catalyst in the presence of a donor solvent. The method is selective toward light lanthanide metal oxides and thus further provides a method for separating light lanthanide metal oxides from heavy lanthanide metal oxides, actinide oxides, and non-lanthanide rare earth element oxides.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: May 23, 2023
    Assignee: Triad National Security, LLC
    Inventors: Jaqueline Loetsch Kiplinger, Louis A. Silks, Ross James Beattie
  • Patent number: 11648225
    Abstract: Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intolerance in a subject, for example, to treat autoimmune disorders, or in combination with an antigenic therapy, such as a protein or gene therapy, to improve the efficacy of the antigenic therapy. The compounds have the following structural formula: wherein values for the variables (e.g., Ring A, L, R1, R2, R3, m) are as described herein.
    Type: Grant
    Filed: August 12, 2022
    Date of Patent: May 16, 2023
    Assignee: Lapix Therapeutics, Inc.
    Inventors: Anas M. Fathallah, Scott D. Larsen, Abdulraouf Ramadan
  • Patent number: 11648545
    Abstract: A transition metal-based heterogeneous carbonylation reaction catalyst has an excellent catalytic activity and selectivity in the carbonylation reaction and is easily separated from a product, by crosslinking polymerizing a transition metal-based homogeneous catalyst unit through a Friedel-Craft reaction. The catalyst may be used in a method for preparing lactone. The transition metal-based heterogeneous carbonylation reaction catalyst allows to produce lactone or succinic anhydride with an epoxide compound while showing a high selectivity, and can be applied in industrial very usefully due to easy separation from the product and thus reusing thereof.
    Type: Grant
    Filed: April 21, 2021
    Date of Patent: May 16, 2023
    Assignee: KOOKMIN UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION
    Inventors: Sungho Yoon, Senkuttuvan Rajendiran, Jianwei Jiang, Kwang Ho Park
  • Patent number: 11642336
    Abstract: The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: May 9, 2023
    Assignee: LOPHORA APS
    Inventors: Jesper Langgaard Kristensen, Anders Asbjørn Jensen, Emil Märcher-Rørsted, Sebastian Leth-Petersen
  • Patent number: 11634395
    Abstract: The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient. A compound represented by Formula (I) [wherein, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents —NH—; X4 represents a hydrogen atom or the like; R1 represents —C(R11)(R12)— or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: April 25, 2023
    Assignee: Taiho Pharmaceutial Co., Ltd.
    Inventors: Seiji Miyahara, Hiroyuki Ueno, Shoki Hara, Yoshio Ogino
  • Patent number: 11634443
    Abstract: Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: April 25, 2023
    Assignee: United Therapeutics Corporation
    Inventors: Kenneth Robert Phares, Hitesh Batra, Liang Guo
  • Patent number: 11633377
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Grant
    Filed: February 8, 2021
    Date of Patent: April 25, 2023
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Marlene Michelle Dressman, Louis William Licamele, Mihael H. Polymeropoulos
  • Patent number: 11633390
    Abstract: The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.
    Type: Grant
    Filed: June 16, 2021
    Date of Patent: April 25, 2023
    Assignee: LOPHORA APS
    Inventors: Jesper Langgaard Kristensen, Anders Asbjørn Jensen, Emil Märcher-Rørsted, Sebastian Leth-Petersen
  • Patent number: 11613536
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: March 28, 2023
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Fenglei Zhang, Song Mei, Wenqing Yao
  • Patent number: 11608322
    Abstract: The present invention refers to a process for direct C—H functionalization, the reagents used in the process and the use thereof for the direct C—H functionalization as well as the so-obtained products.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: March 21, 2023
    Assignee: STUDIENGESELLSCHAFT KOHLE MBH
    Inventors: Tobias Ritter, Florian Berger
  • Patent number: 11607404
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula: in combination with a PARP inhibitor, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: March 21, 2023
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Alfredo C. Castro, Melinda Day, Tyler Maclay, Casey Cameron McComas, Kevin Mills, Joseph Vacca
  • Patent number: 11597708
    Abstract: The present disclosure relates to a class of mammalian heat shock factor (HSF) inhibitors, to pharmaceutical compositions comprising these inhibitors as well as to methods for using the inhibitors. The inhibitors inhibit stress-induced expression from heat shock gene promoters. Furthermore, the inhibitors are cytotoxic to a variety of human cancer cells types.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: March 7, 2023
    Assignee: HSF PHARMACEUTICALS SA
    Inventors: Nuria Vilaboa, Richard W Voellmy